• OKYO Pharma enrolled the first patients in its Phase 3 NEPTUNE pivotal trial of urcosimod for neuropathic corneal pain.
• No clinical results were presented; the study is intended to generate evidence for a potential first-in-class, disease-modifying treatment.
• The trial targets a chronic eye-pain condition with no FDA-approved therapies, supporting a higher-stakes development and commercialization opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060700OMX_____CNEWS_EN_GNW9840359_en) on October 06, 2026, and is solely responsible for the information contained therein.